Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI
In this study, the invesigators look at how a new MRI technique (called amide proton transfer weighted (APTw) chemical exchange saturation transfer (CEST)) can improve treatment for brain tumors through early detection of tumor progression after radiotherapy and/or chemotherapy treatment. An issue with the current trea
| Condition(s) | Glioblastoma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | In this study, the invesigators look at how a new MRI technique (called amide proton transfer weighted (APTw) chemical exchange saturation transfer (CEST)) can improve treatment for brain tumors through early detection of tumor progression after radiotherapy and/or chemotherapy treatment. An issue with the current treatment for patients with a brain tumor, is the inability to detect tumor progression early. An abnormality is seen on MRI scans taken shortly after treatment with radiotherapy in about 30% of patients. This abnormality may be a sign that radiotherapy treatment has worked well and will disappear on its own after a while. However, an abnormality can also be a sign of active tumor tissue. Then it shows that the treatment has not worked well enough. When there is active tumor tiss |
| Who can participate | Inclusion Criteria: * Confirmed diagnosis of glioblastoma based on histopathological or molecular analysis of biopsy after surgery, or suspected of glioblastoma based on medical imaging. * Scheduled to undergo radiotherapy or combined chemo-and radiotherapy * 18 years and older * Able to give informed consent. * Patient will undergo clinically indicated MRIs Exclusion Criteria: * Not able to give informed consent * Contraindication for MRI * Brain pathology affecting CEST contrast, such as recent stroke or earlier cranial radiotherapy, as determined by the principal investigators (PIs) |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Erasmus Medical Center |
| Locations | Amsterdam, Netherlands; Leiden, Netherlands; Rotterdam, Netherlands; Utrecht, Netherlands |
| Start date | 2025-01-15 |
| NCT ID | NCT07121842 |
| Official listing | https://clinicaltrials.gov/study/NCT07121842 |